Amgen’s T-VEC AdCom May Shed Light On How FDA Reviews Intralesional Immunotherapies
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Oncologic Drugs and Cellular, Tissue and Gene Therapies advisory committees will weigh in on a new molecular entity in a nascent field of cancer vaccines April 29; could set precedent for other intralesional drug reviews.